Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Emma, Ádám"'
Publikováno v:
Hematológia−Transzfuziológia. 52:256-259
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::818cbd5311379d84c0b0ad6088eb72e6
https://doi.org/10.1556/2068.2019.52.4.8
https://doi.org/10.1556/2068.2019.52.4.8
Autor:
András Kozma, Péter Reményi, András Bors, Hajnalka Andrikovics, József Harasztdombi, János Dolgos, István Vályi-Nagy, Nóra Meggyesi, Gábor Mikala, Emma Ádám, Petra Kövy, Nóra Lovas, Viktor Lakatos, Adrienn Borsy
Publikováno v:
Hematológia−Transzfuziológia. 52:106-114
Absztrakt: Az izocitrat dehidrogenaz 1 es 2 szomatikus mutaciok az akut myeloid leukemia visszaterő genetikai elteresei, tagabb ertelemben vett epigenetikus hatasmoddal. Az irodalomban ellentmondo ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f4210d0203921100839adeff68e449
https://doi.org/10.1556/2068.2019.52.2.4
https://doi.org/10.1556/2068.2019.52.2.4
Publikováno v:
Hematológia−Transzfuziológia. 52:19-27
Absztrakt: A mielodiszplazias szindromak (MDS) a leggyakoribb hematologiai megbetegedesek koze tartoznak, kulonos tekintettel az idősodő populaciokra. Kozos jellemzőjuk az ineffektiv hemopoezis es kovetkezmenyes citopeniak, valamint az akut leukem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00ce767381420fdda26b6640d7b3adea
https://doi.org/10.1556/2068.2019.52.1.4
https://doi.org/10.1556/2068.2019.52.1.4
Autor:
Péter Masát, Gábor Ottóffy, Blanka Tóth, Katalin Bartyik, Marienn Réti, Csaba Kassa, Réka Simon, Emma Ádám, György Péter, Gergely Kriván, Judit Csomor, Csongor Kiss, Krisztián Kállay, Gabor G. Kovacs, Csaba Bödör
Publikováno v:
Orvosi Hetilap. 159:1710-1719
Abstract: Introduction: Acquired bone marrow failures are rare but fatal diseases in childhood. Since 2013, Hungary has been participating as a full member in the work of the European Working Group on uniform diagnostics and therapy in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93a4a666e8c04c633970048b4122e071
https://doi.org/10.1556/650.2018.31171
https://doi.org/10.1556/650.2018.31171
Autor:
Emma Ádám, András Kozma, Richárd Kiss, Csaba Bödör, Ediz Eyupoglu, Viktória Fésüs, Zoltan Matrai
Publikováno v:
Hematológia−Transzfuziológia. 51:22-29
Absztrakt: Bevezetes: Az elmult evekben megjelent uj celzott terapias szereknek koszonhetően nagy attores tortent a kronikus limfocitas leukemia kezeleseben, kulonosen a magas rizikoju betegcsoport...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2c5c314d3c30ec68e358ad52bc32350
https://doi.org/10.1556/2068.2018.51.1.4
https://doi.org/10.1556/2068.2018.51.1.4
[Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary]
Autor:
Krisztián, Kállay, Judit, Csomor, Emma, Ádám, Csaba, Bödör, Csaba, Kassa, Réka, Simon, Gábor, Kovács, György, Péter, Gábor, Ottóffy, Katalin, Bartyik, Csongor, Kiss, Péter, Masát, Marienn, Réti, Blanka, Tóth, Gergely, Kriván
Publikováno v:
Orvosi hetilap. 159(42)
Acquired bone marrow failures are rare but fatal diseases in childhood. Since 2013, Hungary has been participating as a full member in the work of the European Working Group on uniform diagnostics and therapy in patients with acquired bone marrow fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18e59738b4385872a86fdff2fcb87f37
https://pubmed.ncbi.nlm.nih.gov/30334483
https://pubmed.ncbi.nlm.nih.gov/30334483
Autor:
Katalin Balassa, Hajnalka Andrikovics, Gergely Varga, Tamás Masszi, András Kozma, Attila Tordai, Magdalena Koszarska, Emma Ádám, Gábor Mikala
Publikováno v:
British Journal of Haematology. 168:679-688
Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf0a74899d543b6461cdf29f7836170b
https://doi.org/10.1111/bjh.13197
https://doi.org/10.1111/bjh.13197
Autor:
Szabolcs Tasnády, Csaba Bödör, Attila Gyenesei, Donát Alpár, Péter Farkas, Dóra Marosvári, Dóra Aczél, András Matolcsy, Viktória Fésüs, Marienn Réti, Lilla Reiniger, Richárd Kiss, Emma Ádám, Noémi Nagy, Bence Galik, Ambrus Gángó, András Kozma, Zoltán Mátrai, Ákos Nagy, Szilvia Krizsán
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S279
Introduction: The irreversible Bruton tyrosine kinase (BTK) inhibitor ibrutinib is changing the paradigm of the treatment of chronic lymphocytic leukemia (CLL) with remarkable outcomes in first line as well as in relapsed CLL, including high risk pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fd331bc36d5747f079673a71027ab83
https://doi.org/10.1016/j.clml.2019.07.214
https://doi.org/10.1016/j.clml.2019.07.214
Autor:
András Bors, Emma Ádám, Tamás Masszi, Attila Tordai, Éva Karászi, Zoltán Mátrai, Anikó Szilvási, Gabriella Halm, András Kozma, Hajnalka Andrikovics
Publikováno v:
Pathology oncology research : POR. 23(1)
The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362f4445ada1282d5b50aa104aa7c7eb
https://pubmed.ncbi.nlm.nih.gov/27757836
https://pubmed.ncbi.nlm.nih.gov/27757836
Autor:
Angela Feczko, András Kozma, Nóra Meggyesi, János Dolgos, András Bors, Judit Reichardt, Emma Ádám, Tamas Masszi, Judit Csomor, Attila Tordai, Magdalena Koszarska, Tamás I. Orbán, Hajnalka Andrikovics, Nóra Lovas, Andrea Sipos, Sandor Fekete, Eniko Lehoczky, Éva Karászi, Árpád Bátai
Publikováno v:
Leukemia & Lymphoma. 54:1028-1035
Mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are genetic alterations in acute myeloid leukemia (AML). The aim of our study was to investigate the frequency and prognostic effect of IDH1/2 mutations together followed by an individual analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a964128c7b814bb87529ea47f7384b57
https://doi.org/10.3109/10428194.2012.736981
https://doi.org/10.3109/10428194.2012.736981